Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer

Objective: To explore the regimens and prognoses of second-line therapies for recurrent platinum-resistant ovarian epithelial cancer (OEC). Materials and Methods: The clinical profiles and second-line regimens were retrospectively analyzed for 65 recurrent platinum-resistant OEC patients treated at Zhejiang Provincial Tumor Hospital during January 2003 to January 2013. In conjunction with literature reviews, the second-line therapies for platinum-resistant recurrent OEC were discussed. Results: Their average age was 55.2 years. The stages were I (n=4), II (n=3), III (n=45), and IV (n=13). The predominant type was serous adenocarcinoma (n=47, 72.3%). Chemotherapy was refused (n=14) and resistant (n=51). One case was lost to follow-up and another three withdrew early. An average of four chemotherapeutic courses were offered in 61 cases. Among them, five cases selected chemotherapy after a second operation. The average therapy-free interval (TFI) was 3.5 months. The efficacies were evaluated for 61 cases. CR (n=5) and partial remission (PR, n=22). The overall survival (OS) rate was 43.6% and average progression-free survival (PFS) was 15.44 months. Conclusion: The efficacy of second-line therapy for recurrent platinum-resistant OEC is rather poor and the feasibility and efficacy of second operation are to be further explored.

Ovarian cancer; Resistance; Second-line therapy; Chemotherapy; Secondary cytoreduction.

[1] du Bois A., Quinn M., Thigpen T., Vermorken J., Avall-Lundqvist E., Bookman M., et al.: “2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)”. Ann. Oncol., 2005, 16, viii7.

[2] Leitao M.M. Jr., Chi D.S.: “Surgical management of recurrent ovarian cancer”. Semin Oncol., 2009, 36, 106.

[3] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis”. J. Clin. Oncol., 2002, 20, 1248.

[4] Hennessy B.T., Coleman R.L., Markman M.: “Ovarian cancer”. Lancet, 2009, 374, 1371.

[5] Stuart G.C., Kitchener H., Bacon M., duBois A., Friedlander M., Ledermann J., et al.: “Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference”. Int. J. Gynecol. Cancer, 2011, 21, 750.

[6] Friedlander M., Trimble E., Tinker A., Alberts D., Avall-Lundqvist E., Brady M., et al.: “Clinical trials in recurrent ovarian cancer. Int.J. Gynecol”. Cancer, 2011, 21, 771.

[7] Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al.: “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”. Lancet, 2003, 361, 2099.

[8] Alberts D.S., Liu P.Y., Wilczynski S.P., Clouser M.C., Lopez A.M., Michelin D.P., et al.: “Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinumsensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (South-west Oncology Group Protocol S0200)”. Gynecol. Oncol., 2008, 108, 90.

[9] Rocconi R.P., Case A.S., Straughn J.M. J.r., Estes J.M., Partridge E.E.: “Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis”. Cancer, 2006, 107, 536.

[10] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D., et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum- resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[11] Therasse P., Arbuck S.G., Eisenhauer E.A.,Wanders J., Kaplan R.S., Rubinstein L., et al.: “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada”. J. Natl. Cancer. Inst., 2000, 92, 205.

[12] Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al.: “Gemcitabine plus carboplatin compared with carboplatin in patients with platinumsensitive recurrent ovarian cancer: an intergroup trial of the AGOOVAR, the NCIC CTG, and the EORTC GCG”. J. Clin. Oncol., 2006, 24, 4699.

[13] Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., Gebski V., Heywood M., Vasey P.A., et al.: “Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse”. J. Clin. Oncol., 2010, 28, 3323.

[14] See H.T., Freedman R.S., Kudelka A.P., Burke T.W., Gershenson D.M., Tangjitgamol S., et al.: “Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance”. Int. J. Gynecol. Cancer, 2005, 15, 209.

[15] Zhou H.H., Wang K.L., Chen C.A., Wei L.H., Lai C.H., Hsieh C.Y., et al.: “Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoa: a Taiwanese GynecologicOncology Group study with long-term follow-up”. Gynecol. Oncol., 2006, 101, 423.

[16] Ferrero J.M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al.: “Second-line chemotherapy with pegylated Liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial”. Ann. Oncol., 2007, 18, 263.

[17] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol., 2008, 26, 890.

[18] Ferrandina G., Corrado G., Licameli A., Lorusso D., Fuoco G., Pisconti S., et al.: “Pegylated liposomal doxorubicin in the management of ovarian cancer”. Ther. Clin. Risk Manag., 2010, 6, 463.

[19] Coleman R.L., BradyW.E., McMeekin D.S., Rose P.G., Soper J.T., Lentz S.S., et al.: “A phase II evaluation of nanoparticle, albuminbound (nab) paclitaxel in the treatment of recurrent or persistent platinum- resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2011, 122, 111.

[20] Tillmanns T.D., Lowe M.P., Walker M.S., Stepanski E.J., Schwartzberg L.S.: “Phase II clinical trial of bevacizumab with albumin- bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma”. Gynecol. Oncol., 2013, 128, 221.

[21] Latorre A., De L.M., Catino A., Crucitta E., Sambiasi D., Guida M., et al.: “Epithelial ovarian cancer: second and third line chemotherapy (review)”. Int. J. Oncol., 2002, 21, 179.

[22] Bruchim I., Jarchowsky-Dolberg O., Fishman A. “Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 166, 94.

[23] Ushijima K., Kamura T., Tamura K., Kuzuya K., Sugiyama T., Noda K., Ochiai K.: “Docetaxel/irinotecan combination chemotherapy in platinum/ taxane-refractory and –resistan ovarian cancer: JGOG/WJGOG Intergroup Study”. Int. J. Clin. Oncol., 2013, 18, 126.

[24] Khemapech N., Oranratanaphan S., Termrungruanglert W., Lertkhachonsuk R., Vasurattana A.: “Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®)”. Asian Pac J. Cancer Prev., 2013, 14, 2131.

[25] van der Burg M.E., Vergote I., Onstenk W., Boere I.A., Leunen K., van Montfort C.A.: “Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer”. Eur. J. Cancer, 2013, 49, 1254.

[26] Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., et al.: “Incorporation of bevacizumab in the primary treatment of ovarian cancer”. N. Engl. J. Med., 2011, 365, 2473.

[27] Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al.: “A Phase 3 trial of bevacizumab in ovarian cancer”. N. Engl. J. Med., 2011, 365, 2484.

[28] Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., et al.: “OCEANS: a randomized, double-blind, placebocontrolled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer”. J. Clin. Oncol., 2012, 30, 2039.

[29] Steffensen K.D., Waldstom M., Pallisgard N., Lund B., Bergfeldt K., Wihl J., et al.: “Panitumumab and pegylated liposomal doxorubicin in platinum resistant epithelial ovarian cancer with kras wild-type the palido study, a phase II nonrandomized multicenter study”. Int J Gynecol Cancer, 2013, 23, 73.

[30] Rustin G., van der Burg M., Griffin C., Qian W., Swart A.M.: “Early versus delayed atment of ovarian cancer”. Lancet, 2011, 377, 380.

[31] Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al.: “Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR AGO Study Group, NOGGO, AGO-Austria, and MITO”. Int. J. Gynecol Cancer, 2011, 21, 289.

[32] Eisenkop S.M., Friedman R.L., Spirtos N.M.: “The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma”. Cancer, 2010, 88, 144.

[33] Oksefjell H., Sandstad B., Tropé C.: “The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer”. Ann. Oncol., 2009, 20, 286.

[34] Tian W.J., Jiang R., Cheng X., Tang J., Xing Y., Zang R.Y.: “Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction”. J. Surg. Oncol., 2010, 101, 244.

[35] Bereder J., Glehen O., Habre J., Desantis M., Cotte E., Mounier N., et al.: “Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients”. J. Clin. Oncol., 2009, 27, Abstract 5542.

[36] Deraco M., Virzı S., Raspagliesi F., Puccio F., Macrì A., Famulari C., et al.: “A Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer:a multi-institutional study”. BJOG, 2012, 119, 800.